A study under Australian collaborative trial on steroids use in neonates was done. Which of the following is true –
**Core Concept:** Neonatal steroid therapy, its rationale, and the context of the Australian collaborative trial.
**Why the Correct Answer is Right:** The correct answer, D, refers to the Australian Neonatal Steroids Study (ANS), a large randomized controlled trial conducted in Australia in the 1990s. This study evaluated the benefits and risks of steroid therapy in premature infants and concluded that early administration of dexamethasone significantly reduced mortality and respiratory distress syndrome (RDS) without increasing major adverse effects.
**Why Each Wrong Option is Incorrect:**
A. This option refers to the "NEOPLASTIC" syndrome, which is not related to steroid therapy or the ANS study. It is a term for a group of rare syndromes characterized by congenital heart block and other congenital anomalies due to maternal exposure to medications (e.g., thiazide diuretics).
B. This option is incorrect because it does not match the specific context of the ANS study. The ANS trial focused on steroid therapy in premature infants and its effects on mortality and RDS, not on the concept of "stress-induced fetal adrenal suppression."
C. This option refers to the "Fetal Asphyxia Study" (FAS), which is unrelated to steroid therapy or the ANS study. The FAS was a trial that evaluated the effect of antenatal corticosteroids on neonatal outcomes after acute fetal hypoxia or asphyxia, not steroid therapy in premature infants.
E. This option is incorrect because it does not match the specific context of the ANS study. The ANS trial focused on steroid therapy in premature infants and its effects on mortality and RDS, not the concept of "maternal glucocorticoid therapy."
**Clinical Pearl / High-Yield Fact:** The Australian Neonatal Steroids Study (ANS) is an important landmark trial in neonatology, demonstrating the benefits of early dexamethasone administration on mortality and respiratory outcomes in premature infants without increasing major adverse effects. This study influenced clinical practice guidelines and the use of antenatal corticosteroids to improve neonatal outcomes in high-risk pregnancies.